Haleon (HLN) Stock Forecast & Price Target

$9.52 +0.04 (+0.42%)

(As of 12:21 PM ET)

Haleon - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 6 Analyst Ratings

Sell
0

Hold
1

Buy
5

Based on 6 Wall Street analysts who have issued ratings for Haleon in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 1 has given a hold rating, 4 have given a buy rating, and 1 has given a strong buy rating for HLN.

Consensus Price Target

$10.95
15.02% Upside

According to the 6 analysts' twelve-month price targets for Haleon, the average price target is $10.95. The highest price target for HLN is $10.95, while the lowest price target for HLN is $10.95. The average price target represents a forecasted upside of 15.02% from the current price of $9.52.

Get the Latest News and Ratings for HLN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Haleon and its competitors.

HLN Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$10.95	$10.95	N/A	N/A
Forecasted Upside	15.02% Upside	10.49% Upside	N/A	N/A
Consensus Rating	Buy	Buy	Moderate Buy	Moderate Buy

Tesla Execs are Freaking Out (Ad)

It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

Click here to get the details.

HLN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HLN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Haleon Stock vs. The Competition

Type	Haleon	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	15.32% Upside	26,931.27% Upside	9.84% Upside
News Sentiment Rating	Positive News See Recent HLN News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/1/2024	UBS Group 4 of 5 stars	G. Delmas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/20/2024	Morgan Stanley 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$9.90 ➝ $10.95	+4.78%
8/6/2024	Berenberg Bank 2 of 5 stars	B. Davies Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
8/6/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	O. Nicolai Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
4/17/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
3/26/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy
8/8/2023	Investec Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Hold
5/24/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold
4/4/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
1/31/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		GBX 360 ➝ GBX 364

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:40 PM ET.

Should I Buy Haleon Stock? HLN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, November 4, 2024. Please send any questions or comments about these Haleon pros and cons to contact@marketbeat.com.

Haleon
Bull Case

Here are some ways that investors could benefit from investing in Haleon plc:

Haleon plc's stock price has been steadily increasing, reaching $10.12 on the latest trading day, indicating positive momentum.
Analysts have given Haleon plc favorable ratings, with some even upgrading it to a "strong-buy" and setting a target price of $10.95, suggesting potential for growth.
Haleon plc recently announced a semi-annual dividend, providing investors with a 1.6% dividend yield, which can be attractive for income-focused investors.
Institutional investors and hedge funds have been increasing their positions in Haleon plc, indicating confidence in the company's future performance.
Haleon plc is engaged in the research, development, and sale of consumer healthcare products globally, presenting diversified revenue streams and market exposure.

Haleon
Bear Case

Investors should be bearish about investing in Haleon plc for these reasons:

Haleon plc's PEG ratio of 3.12 may indicate that the stock is overvalued relative to its earnings growth potential, potentially leading to limited upside for investors.
The company's payout ratio of 36.67% suggests that a significant portion of its earnings is being distributed as dividends, which could limit reinvestment for future growth.
Haleon plc's beta of 0.26 indicates low volatility compared to the market, which may result in slower price movements and potentially lower returns for investors seeking high-growth opportunities.
While the company has shown positive earnings per share in the past, sell-side analysts forecast a lower EPS for the current year, signaling potential challenges or uncertainties in the company's financial performance.
Despite analyst ratings, the recent downgrade by The Goldman Sachs Group from "buy" to "neutral" may raise concerns about the company's future prospects and market sentiment.

HLN Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Haleon is $10.95, with a high forecast of $10.95 and a low forecast of $10.95.
: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Haleon in the last year. There is currently 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HLN shares.
: According to analysts, Haleon's stock has a predicted upside of 15.02% based on their 12-month stock forecasts.
: Over the previous 90 days, Haleon's stock had 1 upgrade by analysts.
: Haleon has been rated by research analysts at Morgan Stanley, and UBS Group in the past 90 days.
: Analysts like Haleon more than other "medical" companies. The consensus rating for Haleon is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HLN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)

The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…

Claim your FREE 2024 Gold Guide

This page (NYSE:HLN) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Haleon (HLN) Stock Forecast & Price Target